Abstract:BACKGROUND:Although endocrine therapy impedes estrogen-ER signaling pathway and thus reduces breast cancer mortality, patients remain at continued risk of relapse after tamoxifen or other endocrine therapies. Understanding the mechanisms of endocrine resistance, particularly the role of transcriptional regulation is very important and necessary.METHODS:We propose a two-step workflow based on linear model to investigate the significant differences between MCF7 and OHT cells stimulated by 17β-estradiol (E2) respect to regulatory transcription factors (TFs) and their interactions. We additionally compared predicted regulatory TFs based on RNA polymerase II (PolII) binding quantity data and gene expression data, which were taken from MCF7/MCF7+E2 and OHT/OHT+E2 cell lines following the same analysis workflow. Enrichment analysis concerning diseases and cell functions and regulatory pattern analysis of different motifs of the same TF also were performed.RESULTS:The results showed PolII data could provide more information and predict more recognizably important regulatory TFs. Large differences in TF regulatory mode were found between two cell lines. Through verified through GO annotation, enrichment analysis and related literature regarding these TFs, we found some regulatory TFs such as AP-1, C/EBP, FoxA1, GATA1, Oct-1 and NF-κB, maintained OHT cells through molecular interactions or signaling pathways that were different from the surviving MCF7 cells. From TF regulatory interaction network, we identified E2F, E2F-1 and AP-2 as hub-TFs in MCF7 cells; whereas, in addition to E2F and E2F-1, we identified C/EBP and Oct-1 as hub-TFs in OHT cells. Notably, we found the regulatory patterns of different motifs of the same TF were very different from one another sometimes.CONCLUSIONS:We inferred some regulatory TFs, such as AP-1 and NF-κB, cooperated with ER through both genomic action and non-genomic action. The TFs that were involved in both protein-protein interactions and signaling pathways could be one of the key resistant mechanisms of endocrine therapy and thus also could be new treatment targets for endocrine resistance. Our flexible workflow could be integrated into an existing analytical framework and guide biologists to further determine underlying mechanisms in human diseases.

Integrative Model of Genomic Factors for Determining Binding Site Selection by Estrogen Receptor‐α

Whole-Genome Cartography of Estrogen Receptor Α Binding Sites

Integrative genomics of gene and metabolic regulation by estrogen receptors α and β, and their coregulators

Epigenetic factors that control estrogen receptor alpha (ERα) binding site utilization and specificity in the MCF-7 human breast cancer cell line

A modulated empirical Bayes model for identifying topological and temporal estrogen receptor α regulatory networks in breast cancer

An oestrogen-receptor-|[agr]|-bound human chromatin interactome

An oestrogen-receptor-α-bound human chromatin interactome

Research Resource: Whole-Genome Estrogen Receptor Alpha Binding In Mouse Uterine Tissue Revealed By Chip-Seq

Cooperativity of Co-Factor NR2F2 with Pioneer Factors GATA3, FOXA1 in Promoting ERα Function

Predictive Features of Ligand‐specific Signaling Through the Estrogen Receptor

Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription

Mechanistic analysis of enhancer sequences in the estrogen receptor transcriptional program

In Silico Prediction of Estrogen Receptor Subtype Binding Affinity and Selectivity Using 3D-QSAR and Molecular Docking

Proteomic Analysis of Coregulators Bound to ERα on DNA and Nucleosomes Reveals Coregulator Dynamics.

Multiple-targeting and Conformational Selection in the Estrogen Receptor: Computation and Experiment.

Computational insights into the mechanism of ligand unbinding and selectivity of estrogen receptors.

Understanding Variation in Transcription Factor Binding by Modeling Transcription Factor Genome-Epigenome Interactions.

The Histone Modifications Governing TFF1 Transcription Mediated by Estrogen Receptor

Transcriptional Regulation Prediction of Antiestrogen Resistance in Breast Cancer Based on RNA Polymerase II Binding Data.

Segregating activities of the estrogen receptor in gene regulation

Cellular Reprogramming by the Conjoint Action of ERα, FOXA1, and GATA3 to a Ligand‐inducible Growth State